Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Tumor Lysis Syndrome

• Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
• Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
• Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
• Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
• Fasturtec TLS Treatment / Prophylysis
• Rasburicase in Patients at Risk for Tumor Lysis Syndrome
• Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
• Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
• Rasburicase in Tumor Lysis Syndrome
• Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
• Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
• Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients